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Gene therapies for neurological diseases with autonomic or gastrointestinal involvement
may require global gene expression. Gastrointestinal complications are often associated
with Parkinson’s disease and autism. Lewy bodies, a pathological hallmark of Parkinson’s
brains, are routinely identified in the neurons of the enteric nervous system (ENS)
following colon biopsies from patients. The ENS is the intrinsic nervous system
of the gut, and is responsible for coordinating the secretory and motor functions
of the gastrointestinal tract. ENS dysfunction can cause severe patient discomfort,
malnourishment, or even death as in intestinal pseudo-obstruction (Ogilvie syndrome).
Importantly, ENS transduction following systemic vector administration has not been
thoroughly evaluated. Here we show that systemic injection of AAV9 into neonate or
juvenile mice results in transduction of 25–57% of ENS myenteric neurons. Transgene
expression was prominent in choline acetyltransferase positive cells, but not within
vasoactive intestinal peptide or neuronal nitric oxide synthase cells, suggesting a bias
for cells involved in excitatory signaling. AAV9 transduction in enteric glia is very low
compared to CNS astrocytes. Enteric glial transduction was enhanced by using a glial
specific promoter. Furthermore, we show that AAV8 results in comparable transduction in
neonatal mice to AAV9 though AAV1, 5, and 6 are less efficient. These data demonstrate
that systemic AAV9 has high affinity for peripheral neural tissue and is useful for future
therapeutic development and basic studies of the ENS.
Keywords: AAV9, adeno-associated virus, enteric nervous system, myenteric plexus, functional gastrointestinal
motility disorders, enteric glia, enteric neuropathy, gene therapy
INTRODUCTION
The recent identification of adeno-associated viral vector (AAV)
serotypes that cross the blood brain barrier (BBB) resulted in
unprecedented therapeutic benefit in animal models of neuro-
logical disease (Foust et al., 2010, 2013; Fu et al., 2011; Ahmed
et al., 2013; Garg et al., 2013; Haurigot et al., 2013). AAV9 was
the first serotype described that efficiently crossed the BBB (Foust
et al., 2009). Subsequently multiple groups have demonstrated
that intravenous injection of AAV9 into mice, rats, cats and non-
human primates produces robust transduction in the central
nervous system (CNS) (Duque et al., 2009; Tatom et al., 2009;
Bevan et al., 2011). Intravenous injection of AAV9 in neonatal
mice results in primarily neuronal transduction throughout the
brain and spinal cord, but preferentially targets astrocytes when
injected in mice greater than 2 weeks of age (Foust et al., 2009).
Similar CNS transduction patterns have been reported with other
AAV serotypes following systemic delivery (Zhang et al., 2011).
AAV’s affinity for nervous tissue suggests that the peripheral ner-
vous systems are likely transduced following systemic injection.
Gene delivery to large peripheral neuronal networks such as the
autonomic nervous system (ANS) and enteric nervous system
(ENS) may be beneficial for treatment of global neurological dis-
ease. To date, transduction in peripheral neurons has not been
thoroughly investigated.
The ENS is often referred to as “the little brain in the gut” and
is estimated to have as many neurons as the spinal cord (Wood,
2000). The ENS is embedded within the mucosal and muscu-
lar layers throughout the length of the gastrointestinal (GI) tract
and enteric neurons and glial cells are arranged into two gan-
glionated plexuses called the submucosal and myenteric plexus,
respectively. The submucosal plexus senses and reacts to stretch
and chemical changes induced by luminal contents while the
myenteric plexus coordinates motor function of smooth muscle.
Dysfunction of the ENS is linked to a series of GI disorders that
are often chronic and prevalent in pediatric and adult populations
(Fukudo et al., 2012; Yeung and Di Lorenzo, 2012). For example,
functional GI motility disorders (FGIMD) are estimated to affect
5–30% of adults and children in the United States (Saito et al.,
2002; Camilleri et al., 2005). In FGIMDs, disruption of GI nerves
and/or muscle can cause chronic gastroesophageal acid reflux,
constipation, abdominal pain and bloating. However, etiology is
not well understood and suitable long-term therapies do not exist
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(Fukudo et al., 2012). The ENS is also implicated in functional
gastrointestinal disorders (FGIDs) such as dyspepsia and irrita-
ble bowel syndrome that affect 15–20% of the US population.
Further, the ENS is a potential therapeutic target for diarrheal
disorders and inflammatory bowel diseases (IBD). GI neuromus-
cular disorders, such as chronic intestinal pseudo-obstruction
(CIP), are also poorly understood (Gabbard and Lacy, 2013). In
someCIP cases, myenteric neurons contain proteinaceous nuclear
inclusions and evidence of apoptosis, presumably causing the
GI dysfunction (El-Rifai et al., 2006; Gabbard and Lacy, 2013).
Interestingly, GI dysfunction also commonly occurs in patients
with autism or Parkinson’s disease (Anderson et al., 2007; Buie
et al., 2010; Wakabayashi et al., 2010; Natale et al., 2011; Mazurek
et al., 2012). Parkinson’s disease Lewy bodies in ENS neurons
can be identified in tissue biopsies (Derkinderen et al., 2011),
suggestive that peripheral neurons are also affected in CNS dis-
eases. Beyond diseases, aging is a risk factor for GI dysfunction
(Camilleri et al., 2008; Wiskur and Greenwood-Van Meerveld,
2010). Chronic constipation is common in the elderly and can
be associated with idiopathic ENS neuron degeneration (Sanchez
and Bercik, 2011).
In addition to neurons, the ENS contains enteric glial cells
(EGCs) that are similar to CNS astrocytes. Enteric glia, like CNS
astrocytes, are essential for maintaining homeostasis and regulat-
ing neural circuit activity (Gulbransen and Sharkey, 2012). EGCs
likely serve as key regulators of intestinal inflammation in ani-
mals and humans. Their ability to mediate immune responses
in vivo was suggested as a possible pathologic mechanism in
Crohn’s Disease (Cornet et al., 2001). Data suggest that there
is an impairment of the glial network in non-inflamed regions
of the gut mucosa in patients with Crohn’s Disease, as evidence
by a decrease in GFAP immunoreactivity in glia (Cornet et al.,
2001). Overall, EGCs like astrocytes in the brain mediate glial
transmission, and regulate synaptic signaling, synaptic plastic-
ity, network excitability and inflammation. EGCs contribute to
the onset and development of intestinal inflammation’ and are
important in the understanding of GI inflammation occurring
in IBD, enterocolitis, and gut infections (Savidge et al., 2007;
Vijayaraghavan, 2009; Cirillo et al., 2011; McClain et al., 2014;
Turco et al., 2014).
Together, the lack of available therapies for ENS is a major
health problem and is an urgent need. Due to its safety and sus-
tained expression, systemic AAV gene therapy may be a useful
approach to treat and study the ENS and its associated disor-
ders. AAV transduction of the ENS has been reported but not well
characterized (Fu et al., 2011; Rahim et al., 2011; Mattar et al.,
2013; Schuster et al., 2014) likely due to the unique architecture
and intricate dissection techniques required for study. The goal
of the current work was to characterize AAV9 transduction effi-
ciency and cell types targeted in the myenteric plexus following
intravenous injection into neonatal or juvenile mice. In con-
trast to age dependent transduction patterns in the mouse CNS
(Foust et al., 2009), we show that self complementary AAV9 injec-
tion results in extensive myenteric neuron transduction at both
neonate and juvenile time points in all regions of the GI tract.
Furthermore, AAV9 transduction of EGCs pales in comparison
to CNS astrocytes. Additionally, we also examined transduction
of self complementary AAV serotypes 1, 5, 6, and 8 in the
myenteric plexus and show that they differ greatly in transduction
efficiency.
MATERIALS AND METHODS
ANIMALS
A total of 20 male or female FVB mice were used for these
studies. Postnatal day 1 (P1) pups were used in all neonatal injec-
tion studies and juvenile mice were used beginning at postnatal
day 21 (P21). Following vector injection procedures, neonatal
mice remained with the dam until weaning. Mice were housed
with same-sex littermates and given food and water ad libi-
tum in a constant 12 h light/dark cycle room in the AAALAC
approved Ohio State University Biomedical Research Tower
vivarium. All animal procedures were approved by the Ohio
State University Institutional Laboratory Animal Care and Use
Committee.
AAV VECTOR PRODUCTION AND PURIFICATION
All vectors used in these studies were produced by the University
of Massachusetts Medical School Viral Vector Core. Self com-
plementary AAV (scAAV) genomes were engineered to encode
the green fluorescent protein (GFP) transgene under the control
of the chicken-β-actin/cytomegalovirus hybrid (CB) promoter,
flanked by AAV2 inverted terminal repeats. Virus was packaged
by triple transfection of HEK293 cells with an adenovirus helper
plasmid and plasmids containing the AAV2 rep gene and AAV1,
5, 6, 8, or 9 cap genes. Vectors were purified by cesium chloride
gradient and titers were determined by qPCR. Vector titers were
scAAV1- 2.4 × 1013, scAAV5- 9.0 × 1012, scAAV6- 5.0 × 1012,
scAAV8- 1.0 × 1013, and scAAV9- 1.0 × 1013 vector genomes
(vg)/ml.
AAV INJECTIONS
Intravaenous injections of scAAV9-CB-GFP or scAAV8-CB-GFP
in neonatal (P1) and juvenile (P21) mice were completed as pre-
viously described (Foust et al., 2009; Gombash Lampe et al.,
in press)
NEONATES
A dissecting microscope and fiber-optic light source were used for
visualization of the temporal face vein. First, neonatal mice were
rested on a bed of ice for anesthetization and a 3/10 cc 30 gauge
insulin syringe (Terumo Medical Corp., Elkton, MD) was loaded
with 1 × 1011 vg/ml scAAV9-CB-GFP or 5 × 1010 vg/ml scAAV1,
5, 6, 8, or 9-CB-GFP. Viral particles supplemented with phos-
phate buffered saline (PBS, 0.01M, pH 7.4) for a total volume
of 50μl were injected into the face vein. Pups were then warmed,
returned to their home cage, and rubbed in bedding to prevent
rejection by the mother. Neonatal animals were sacrificed 30–60
days post-injection for myenteric analysis.
JUVENILES
Juvenile tail vein injections were performed on P21 mice. Mice
were restrained in an illuminated tail vein injection platform
(Braintree Scientific Inc., Braintree, MA). Prior to injection, the
tail was swabbed with alcohol, then 3/10 cc 30 gauge insulin
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syringes were used to inject scAAV9-CB-GFP for a final dose of
2 × 1012 vg. Mice were then returned to their home cages.
WHOLE MOUNT PREPARATIONS
Wholemount longitudinal muscle-myenteric plexus (LMMP) tis-
sues were microdissected as previously described (Wang et al.,
2007). Briefly, the entire gastrointestinal tract beginning at the
lower esophagus through the rectum was removed from eutha-
nized mice and rinsed in room temperature PBS. Next, regions of
the gastrointestinal tract (stomach, duodenum, jejunum, ileum,
cecum, and colon) were separated, opened, and pinned flat with
the luminal side up on a Sylgard (Dow Corning, Midland, MI)
base in 100mm cell culture dishes. Under a dissecting micro-
scope, fine forceps were used to remove the muscosa, submucosa,
and circular muscle to expose the myenteric plexus on the surface
of the longitudinal muscle. Immunohistochemistry was then used
to observe transgene expression, neurons, and glial cells within
the myenteric plexus.
IMMUNOHISTOCHEMISTRY
LMMP tissues were fixed in Zamboni’s fixative (4%
paraformaldehyde and 0.2% piciric acid in 0.1M PBS; #1459,
Newcomer Supply, Middleton, WI) overnight at 4◦C. The
next day, tissues were rinsed in PBS until clear. Tissues were
transferred to glass slides and incubated in blocking buffer [10%
normal donkey serum (NDS), 0.5% Triton-X 100 in PBS] for 2 h
at room temperature. Tissues were then incubated in appropriate
primary antisera overnight at 4◦C against green fluorescent
protein (GFP; 1:500; ab13970, Abcam, Cambridge, MA), HuD
(1:25; A-21271, Life Technologies, Eugene, OR), S100 Protein
Ab-2 (S100; 1:200; RB-044-A0, Thermo Scientific, UK), choline
acetyltransferase (ChAT; 1:50; AB144P, Millipore, Temecula,
CA); vasoactive intestinal peptide (VIP; 1:200; Abcam), neuronal
nitric oxide synthase (nNOS; 1:200; ab1376, Abcam), calretinin
(1:200; CG1, Swant, Switzerland), or calbindin D-28K (1:200;
AB1778, Millipore). The next day, tissues were rinsed 4 times
for 10min in PBS, then incubated in appropriate Alexa Fluor
secondary antibodies at 1:200 for 2 h at room temperature.
Antibody dilutent was 3% NDS, 0.5% Triton-X 100 in PBS.
Tissues were then rinsed and slides were coverslipped with 2.5%
PVA/DABCO. Fluorescent images were captured on an Olympus
FV 100 Spectral Confocal system (Melville, NY) in the Ohio State
University Campus Microscopy and Imaging Facility.
QUANTIFICATION OF MYENTERIC NEURONS
Fluorescently stained whole mount tissues were viewed with a
Zeiss fluorescent microscope equipped with the appropriate fil-
ters to distinguish CY3, CY5, and FITC flurophores. Myenteric
ganglia in the stomach, duodenum, jejunum, ileum, cecum, and
colon were viewed at 40× for counting of HuD positive and
GFP positive cells. Total neurons counted in each region are
recorded in Figure 3A. HuD and GFP positive neuron counts
were collected only from the colon for scAAV8-CB-GFP and
low-dose scAAV9-CB-GFP (5 × 1010 vg) injected mice. For oral-
aboral preference analysis in the colon, LMMP colon preparations
in the correct orientation were separated into nine 1 cm seg-
ments. Numbers of HuD and GFP positive neurons in 10 ganglia
in each segment were recorded, resulting in approximately 5000
HuD positive neurons counted within groups. Data is reported as
the percentage of GFP positive neurons ± standard error of the
mean (SEM).
STATISTICS
A one-way repeated measures analysis of variance was used to
compare percentages of neuronal transduction across the oral
to aboral axis of the colon in neonatal and juvenile injected
mice. A Student’s t-test was used to compare transduced neuron
counts following scAAV8-CB-GFP or scAAV9-CB-GFP injection.
All results are listed as the mean ± s.e.m.
RESULTS
AAV9 EFFICIENTLY TRANSDUCES MYENTERIC NEURONS FOLLOWING
INTRAVENOUS INJECTION INTO NEONATE AND JUVENILE MICE
To investigate AAV9 ENS transduction, neonatal mice (P1)
were injected in the temporal vein with 1 × 1011 vg of self
complementary (sc) AAV9-CB-GFP. Three weeks post-injection,
immunolabeling for GFP of the myenteric plexus revealed robust,
widespread expression in neuronal cell bodies and fibers. GFP
expression was detected in all regions of the gastrointestinal
tract, including the esophagus (not shown), stomach, duode-
num, jejunum, ileum, cecum, and the colon (Figure 1). GFP
localized in HuD positive cells in all regions of the GI tract. No
GFP expression was observed in S100 positive enteric glia in any
region, suggesting expression was confined to myenteric neurons
(Supplementary Figure 1). Intravenous AAV9 preferentially tar-
gets neurons in neonatal mice and astrocytes in juvenile injected
animals (Foust et al., 2009). To determine if ENS transduction
also followed this pattern, 2 × 1012 vg of scAAV9-CB-GFP was
injected into the tail vein of P21 mice. Similarly to injected
neonates, GFP and HuD immunolabeling revealed widespread,
robust transgene expression through all regions of the gastroin-
testinal tract (Figure 2). GFP expression was again limited to
myenteric neurons and their projections and was not expressed
in intraganglionic glial cells along the entire tract. The paucity
of enteric glia transduction was surprising because we previously
reported that scAAV-CB-GFP expression was highly efficient in
CNS astrocytes (Foust et al., 2009). Others have shown that the
neuronal tropism of AAV vectors can be redirected to glia by driv-
ing transgene expression under the GFAP promoter (Burger et al.,
2004; Taymans et al., 2007; Lawlor et al., 2009; von Jonquieres
et al., 2013; de Leeuw et al., 2014). GFAP expression is common to
CNS astrocytes and enteric glia (Gulbransen and Sharkey, 2012).
Therefore, we engineered a single stranded AAV9-GFAP-GFP vec-
tor and intravenously injected neonate mice with 1 × 1011 vg
(n = 3). Mice were euthanized between 30 and 60 days post-
injection and the myenteric plexus was labeled for GFP, GFAP,
and S100. GFP expression was predominantly in enteric glia in
myenteric ganglia (Supplementary Figure 2). Though rare, an
occasional cell with neuronal morphology was detected (not pic-
tured). Overall, the number of transduced glial cells was low
(<5%). Further optimization is needed to increase glial targeting,
however, these data show that AAV9 mediated transgene expres-
sion in the ENS can be biased toward enteric glia by changing the
viral genome.
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FIGURE 1 | Green fluorescent protein (GFP) expression in the
myenteric plexus following intravenous injection of scAAV9-CB-GFP
into neonatal mice. Intravenous injection of scAAV9-CB-GFP into P1 mice
resulted in GFP (green, A–F) expression in neurons (HuD, red, G–L) in the
stomach (A,G,M), duodenum (B,H,N), jejunum (C,I,O), ileum (D,J,P),
cecum (E,K,Q), and in the colon (F,L,R). Arrows in merged images (M–R)
point to GFP expressing neurons. Arrowheads identify untransduced
neurons. Scale bars are 100μm.
Next we quantified GFP expressing myenteric neurons in mice
that received scAAV9-CB-GFP injections as neonates or juvenile
mice (n = 3 each group). In neonatal mice, average neuronal
transduction ranged from 25 to 43% depending on GI region
examined. GFP expression was most abundant in neurons of
the ileum and colon, reaching 41.3 ± 2% and 43.7 ± 3%,
respectively. Transduction ranged from 38 to 57% in juvenile
injected mice. GFP expression was highest in the colon (47.1 ±
4%), stomach (51.5 ± 4%), and ileum (57.2 ± 3%). The dif-
ference in transduction efficiencies likely reflects differences in
the doses administered (neonates = 6.7 × 1010 vg/g body weight
and juveniles = 1.4 × 1011 vg/g body weight). These results are
summarized in Figure 3A and demonstrate that efficient trans-
duction of myenteric neurons can be achieved regardless of age of
administration.
AAV9 MEDIATED GFP EXPRESSION ALONG THE ORAL-ABORAL AXIS OF
THE COLON
Regions of the colon from oral to distal end (e.g., ascending,
transverse, descending, sigmoid and rectum) are associated with
anatomical differences in the size of ganglia and neuronal den-
sity (Hasler et al., 1990; Sibaev et al., 2003), as well as distinct
functions and motor patterns of activity. To examine if myen-
teric plexus transduction was biased along the oral to aboral axis,
GFP expression was analyzed in 1 cm colon segments (labeled
1–9; oral to aboral). Segments from P1 treated colons (n = 3) had
GFP expression in 37–51% of myenteric neurons with no appar-
ent gradient of GFP expression (Figure 3B). The highest regions
of scAAV9 transduction were in segments 2 (50.8 ± 3%) and 8
(48.2 ± 3%), while the lowest were in segments 1 (36.9 ± 4%)
and 5 (36.7 ± 2%). In colons of P21 injected animals (n = 3),
GFP transduction peaked in segment 8 (62.1 ± 3%) followed
closely by segments 6, 1, and 3 (58.4 ± 2, 53.3 ± 2, and 52.5 ±
3%, respectively). Segments 7 and 9 had the lowest percentage
of GFP positive myenteric neurons (44.3 ± 3 and 44.5 ± 4%,
respectively). A One-Way repeated measures ANOVA revealed no
significant differences in GFP positive neurons between segments
within groups (p > 0.05). Comparisons between ages were not
considered.
CHEMICAL CODING OF AAV9 TRANSDUCED NEURONS IN THE
MYENTERIC PLEXUS
Myenteric neurons can broadly be classified into motor neu-
rons, interneurons and sensory neurons (Furness et al., 2003).
These categories can be further delineated based on the direc-
tion of axonal projections and chemical markers present in
cells, referred to as chemical coding (Costa et al., 1986; Lomax
and Furness, 2000). To determine if specific neuronal types
were preferentially transduced by scAAV9, LMMP preparations
from the colon were triple labeled for GFP, HuD, and either
calretinin, calbindin, nNOS, VIP, or ChAT. Neuronal subtypes
expressing ChAT include excitatory motor neurons projecting
to circular and longitudinal muscles, ascending and descend-
ing interneurons, and some sensory neurons (Harrington et al.,
2010). VIP and nNOS labeling occurs in inhibitory motor neu-
rons projecting to circular and longitudinal muscles (Furness,
2000). Calretinin expression occurs predominantly in ascending
interneuron populations and less frequently in excitatory motor
neurons (Bergner et al., 2014). Calbindin expression is com-
monly found in descending interneurons and sensory neurons
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FIGURE 2 | Green fluorescent protein (GFP) expression in the myenteric
plexus following intravenous injection of scAAV9-CB-GFP into juvenile
mice. Intravenous injection of scAAV9-CB-GFP into P21 mice resulted in
robust GFP (green, A–F) expression in neurons (HuD, red, G–L) in the
stomach (A,G,M), duodenum (B,H,N), jejunum (C,I,O), ileum (D,J,P), cecum
(E,K,Q), and in the colon (F,L,R). Arrows in merged images (M–R) point to
GFP expressing neurons. Arrowheads identify untransduced neurons. Scale
bars are 100μm.
(Costa et al., 1986; Furness, 2000). scAAV9 mediated GFP expres-
sion was common in neuronal cell bodies labeled with ChAT,
calretinin, and calbindin when intravenously injected into P1
or P21 mice (Figures 4A–I). ChAT or calretinin labeled fiber
tracts were also GFP positive. In contrast, GFP expression within
VIP or nNOS positive neurons or interganglionic fibers was rare
(Figures 4J–O). GFP expression was not detected in S100 positive
glial cells (Figures 4P–R). Together, these data suggest preferential
scAAV9-CB-GFP transduction of neurons involved in excitatory
signaling.
TRANSDUCTION OF THE MYENTERIC PLEXUS FOLLOWING
INTRAVENOUS INJECTION OF scAAV1, scAAV5, scAAV6, AND scAAV8
IN NEONATAL MICE
To determine if a serotype capable of vascular escape was required
to transduce the myenteric plexus, we tested scAAV serotypes
that efficiently traverse (AAV6, 8, and 9) or are inhibited (AAV1
and 5) by endothelial cell barriers (Supplementary Figure 3). We
intravenously injected neonate mice with 5 × 1010 vg of either
scAAV1, scAAV5, scAAV6, scAAV8, or scAAV9 that encoded
identical expression cassettes (scAAV-CB-GFP). Animals were
euthanized 30–60 days post-injection and the myenteric plexus
was immunolabeled for GFP, HuD, and S100. Immunolabeling
revealed limited to no transduction of myenteric neurons or
glial cells following AAV1, 5, and 6 injection (Figures 5A–C).
scAAV8 injection produced robust, widespread transduction in
the myenteric plexus in all regions of the GI tract. AAV8mediated
GFP expression was observed in myenteric neurons, fiber tracts,
and some intraganglionic glial cells (Figures 5D, 6). Neuronal
transduction in the colons of scAAV8 and scAAV9 treated mice
was quantified. A total of 3029HuD positive and 599 GFP positive
neurons from 91 ganglia were counted in scAAV8 injected mice.
A total of 3366 HuD positive and 539 GFP positive neurons in
90 ganglia were counted from scAAV9 injected mice (Figure 5F).
A Student’s t-test revealed significantly higher percentage of
myenteric neuron transduction in scAAV8 injected mice (average
20.6 ± 1%) compared to scAAV9 injected mice (15.8 ± 1%) at
the 5 × 1010 vg dose [t(179) = 4.11, p < 0.001]. These data show
that AAV must be able to escape vasculature following systemic
injection to efficiently transduce myenteric plexus.
AAV8 MEDIATED TRANSGENE EXPRESSION IN MYENTERIC NEURON
SUBTYPES AND ENTERIC GLIA
LMMP tissues from scAAV8-CB-GFP were fluorescently
immunolabeled for GFP, HuD, and VIP, nNOS, calretinin,
calbindin, and ChAT. Similarly to scAAV9, scAAV8 mediated
GFP expression occurred in ChAT, calretinin and calbindin
positive myenteric neurons (Figures 6A–I). Additionally, robust
GFP expression was detected in calretinin and calbindin positive
interganglionic fibers. Contrary to scAAV9, GFP expression was
also detected in VIP and nNOS expressing inhibitory motor
neurons with limited co-expression in fibers (Figures 6J–O).
Furthermore, GFP expression was sparingly detected in
intraganglionic S100 positive EGCs (Figures 6P–R).
DISCUSSION
Prior to this work, AAV transduction of the GI tract and the
ENS was not well characterized (Fu et al., 2011; Rahim et al.,
2011; Mattar et al., 2013; Schuster et al., 2014). Understanding
of AAV transduction in the ENS is essential for therapeutic
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FIGURE 3 | Quantification of GFP expressing myenteric neurons. (A) Total
transduced and untransduced neuron counts in each gastrointestinal region
in mice injected either at P1 (neonates, n = 3) or P21 (juveniles, n = 3).
Transduction of HuD positive neurons ranged from ∼25 to ∼43% in
neonatally injected mice. Transduction ranged from ∼42 to 57% in juvenile
injected mice. (B) Quantification of GFP myenteric neurons across the oral to
aboral length of the colon revealed no transduction differences between
proximal and distal colon segments in neonatal and juvenile injected mice.
development in neurological disease, FGIMD, GI neuromuscu-
lar disease, FGID’s, IBS, diarrheal diseases and IBD. Here we
examined transduction of the myenteric plexus following sys-
temic delivery of scAAV9 and additional serotypes scAAV1, 5, 6,
and 8. scAAV9 transduced myenteric neurons along the entire GI
tract when systemically administered to neonate or juvenile mice.
Dosing was not controlled for body weight across ages therefore
comparisons of transduction efficiency dependent on age cannot
be made. Despite that, scAAV9 transduction was robust when
administered at either age, achieving transduction of 25–57%
of myenteric neurons across various regions of the GI tract.
Structural variations along the colon did not affect transduc-
tion in the myenteric plexus. Furthermore, we report that AAV
serotypes that efficiently traverse the BBB in the CNS are neces-
sary but may not be sufficient for myenteric neuron transduction
(Figure 5 and Supplementary Figure 3).
The extensive overlap of the more than 40 neurotransmitters
identified in the ENS limits interpretation of the cells targeted
by AAV (Furness, 2012). However, we examined colocaliza-
tion between GFP and known ENS markers including ChAT,
VIP, nNOS, calbindin, calretinin, and S100. scAAV9 transgene
expression was more common in neurons involved in excitatory
neurotransmission (ChAT), sensation (calbindin), and ascend-
ing signaling (calretinin). In general, viral tropism is dictated by
the capsid and expression cassette and is somewhat malleable.
For example, substitution of a GFAP promoter for the ubiq-
uitous chicken β-actin (CB) promoter in scAAV9 was effective
at targeting enteric glia (Supplementary Figure 2). Because the
CB promoter produces robust expression in CNS astrocytes but
not in enteric glia, this finding further emphasizes that enteric
glia are similar yet distinct from CNS astrocytes (Gulbransen
and Sharkey, 2012; McClain et al., 2014). Importantly, the
term “enteric glia” encompasses multiple subtypes of glial cells
with divergent morphologies and localities within the gut wall
(Gulbransen and Sharkey, 2012). Cellular properties of enteric
glia subtypes, their interactions with ENS vasculature, and how
those factors compare to CNS astrocytes is not well understood.
Functional and physiological disparities fromCNS astrocytes may
explain contrasting efficiencies in glial cell transduction within
the ENS and CNS following juvenile AAV9 systemic delivery. The
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FIGURE 4 | Chemical coding of transduced myenteric cells in the colon
after systemic scAAV9-CB-GFP injection. GFP expression (B,E,H,K,N,Q)
was detected in choline acetyltransferase (ChAT, A,C) positive, calbindin
positive (D,F), and calretinin positive (G,I) myenteric neurons and some
intraganglioninc fibers. ChAT staining is indicative of excitatory motor
neurons and ascending and descending projecting interneurons. Calbindin
and calretinin calcium binding proteins are indicative of excitatory motor
neurons and some classes of interneurons. Transduction was rare or
completely absent in vasoactive intestinal peptide (VIP, J,L) positive or
neuronal nitric oxide synthase (nNOS, M,O) positive cells. VIP and nNOS
staining is associated with inhibitory motor neuron and descending
interneurons. GFP did not co-localize with S100 positive glial cells (P,R).
Arrows indicate co-expression while arrowheads indicate no GFP
expression. Scale bars are 100μm.
FIGURE 5 | Transduction efficiency in the myenteric plexus is
dependent on AAV serotype. Neonatal mice were intravenously injected
with scAAV1 (A), scAAV5 (B), scAAV6 (C), scAAV8 (D), or scAAV9-CB-GFP
(E) (final dose 5 × 1010 vg/ml). Green fluorescent protein (GFP, green)
immunofluorescence in the myenteric plexus of the colon reveled absent to
minimal GFP expression in neurons (HuD, red) following scAAV1, scAAV5,
and scAAV6 intravenous injection. Robust GFP expression was detected in
neurons in scAAV8 (D) and scAAV9 (E) injected mice. Total enumeration
counts of neurons in the myenteric plexus of the colon revealed that 19.7 ±
0.9% or 16.0 ± 0.2% of neurons were transduced in scAAV8 and scAAV9
injected mice, respectively (F, ∗p < 0.001). Scale bars are 100μm.
emerging role of enteric glia in the tripartite synapse of the ENS as
in CNS, in GI motility, and their likely contribution to GI motility
disorders and gut inflammation make them an important target
within the ENS and merits further investigation (Lomax et al.,
2005; Ren et al., 2011; Gulbransen and Sharkey, 2012; McClain
et al., 2014). Further variation in enteric cell tropism is provided
by changing the AAV capsid.
Despite all of the tested serotypes having neuronal tropisms
in the CNS, only scAAV8 had robust myenteric transduction
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FIGURE 6 | Chemical coding of transduced myenteric cells in the colon
after systemic scAAV8 injection. Similarly to scAAV9, systemic injection
of scAAV8-CB-GFP produced GFP expression (B,E,H,K,N,Q) was detected
in ChAT (A–C), calbindin (D–F), and calretinin (G–I) positive excitatory
neurons, interneurons and intraganglionic fibers. Additionally, GFP
expression was also detected in VIP (J–L) and nNOS (M–O) positive
inhibitory neurons, interneurons, and intraganglionic fibers. GFP expression
was occasionally detected in S100 positive enteric glia (P–R). White arrows
in merged images indicate transduced cells. Scale bars are 100μm.
similar to scAAV9. Interestingly, scAAV8 transduction included
VIP and nNOS neurons and enteric glia that were rarely seen
in scAAV9 tissue. This broader transduction profile seen with
scAAV8 suggests that the AAV catalog may allow for powerful
customization of ENS gene delivery. Differences in receptors for
scAAV8 and scAAV9 likely contribute to the observed differences
in myenteric transduction (Akache et al., 2006; Bell et al., 2011;
Shen et al., 2011). In contrast to scAAV8 and 9, systemic injec-
tion of scAAV1, 5, and 6 produced few to no GFP positive cells.
These data suggest that vascular escape is a requirement for AAV
mediated myenteric neuron transduction and is in agreement
with prior work showing that ENS vasculature is not fenestrated
(Gershon and Bursztajn, 1978).
Systemic AAV gene delivery may be beneficial for multi-
system neurological disease. Patients with CNS disorders like
Alzheimer’s, Parkinson’s, autism spectrum disorders, spinal cord
injury and neuromuscular diseases have reported GI complica-
tions which likely involve ENS pathology (Anderson et al., 2007;
Buie et al., 2010; Wakabayashi et al., 2010; Natale et al., 2011;
Mazurek et al., 2012). Many of these disorders are the sub-
jects of gene therapy studies (Kaplitt et al., 2007; Foust et al.,
2010; Muramatsu et al., 2010; Garg et al., 2013). Currently,
the high doses of systemic AAV delivery required for efficient
CNS transduction limits usage in adults. However, delivery into
cerebrospinal fluid (CSF) or direct CNS injection in combi-
nation with low dose systemic delivery could simultaneously
treat CNS and GI aspects of neurological disease (Bevan et al.,
2011; Samaranch et al., 2012). Indeed, Parkinson’s and spinal
cord injury patients list GI dysfunction as severely impact-
ing quality of life (Sakakibara et al., 2001; Anderson, 2004).
Therefore, ideal therapies for these disorders will also remedy GI
dysfunction.
The current findings are also important for studies of ENS
biology. Transgenic approaches to study the ENS can be ham-
pered by the degree of overlap between ENS and CNS cells. For
example, most cre drivers designed for nervous tissue express in
both the CNS and ENS which complicates experimental design.
Therefore, development of AAV vectors with restricted expression
would be useful in basic studies of ENS biology. Such a vector
could be used to deliver a cDNA or RNAi construct to manipu-
late gene expression exclusively within the ENS. Additionally, an
AAV can exogenously express cre-recombinase and add a tem-
poral component to ENS studies. Alternatively, AAV vectors can
be used in knockout animals to maintain tissue specific expres-
sion of a targeted gene. Gene expression can be restricted to the
CNS by intracerebroventricular (ICV) injection. ICV injection
in mice results in minimal gene expression in peripheral tissues.
Following ICV injection, resulting animals would be chimeric for
the knocked out gene; with CNS expression maintained and ENS
expression depleted. Finally, the current data can likely be trans-
lated to other species, such as guinea pig or non-human primates,
where genetic tools are limited. The pattern of scAAV9 transgene
expression has been consistent across mice, rats, cats and non-
human primates. This would allow fluorescent labeling or genetic
manipulation of the ENS in novel species.
In summary, results from the current study demonstrate that
systemic AAV delivery can efficiently target the myenteric plexus
in the entire gastrointestinal tract in mice. These data should lay
the foundation for therapies directed at GI motility disorders,
neurological disease and inflammatory diseases affecting enteric
glia. Future efforts will refine the ENS neuronal and glial cell sub-
types targeted and evaluate transduction within the submucosal
plexus.
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Supplementary Figure 1 | GFP expression is confined to myenteric
neurons. Systemic injection of scAAV9-CB-GFP resulted in transduction of
myenteric neurons in both neonatal (P1, A–E) and juvenile (P21, F–J)
injected mice. Co-expression in neurons but not enteric glia was
confirmed by immunohistochemistry for GFP (A,F), S100 identifying
enteric glia (B,G), and HuD identifying myenteric neurons (D,I). Merged
images show GFP expression in neurons only (C,H,E,J). Arrows show
GFP expression in neurons that does no coincide with S100 glia staining.
Scale bars are 100 or 50μm in insets.
Supplementary Figure 2 | Altered myenteric cell type transduction
following change in AAV promoter. GFP expression (A) was detected
exclusively in S100 positive (B,C) myenteric glial cells following
intravenous administration of ssAAV9-GFAP-GFP.
Supplementary Figure 3 | AAV Transduction in the Brain and Spinal Cord
following intravenous injection. GFP immunofluorescence was detected
in neurons (NeuN, cyan) and astrocytes [glial fibrillary acidic protein
(GFAP), red] in the brains and spinal cords of scAAV1 (A,F), scAAV6 (C,H),
scAAV8 (D,I), and scAAV9 (E,J) CB-GFP intravenously injected mice. No
CNS transduction occurred in scAAV5 (B,G) injected animals. Arrowheads
indicate transduced neurons (co-labeling with NeuN) and arrows indicate
transduced astrocytes (co-labeled with GFAP). Scale bars are 100μm.
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